Mutations and MRD: clinical implications of clonal ontogeny

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Measurable residual disease (MRD) is a critical prognostic marker in acute myeloid leukemia (AML).
• Current MRD assessment shows limitations, with frequent outliers of MRD negativity with relapse and MRD positivity without relapse.
• Understanding the biological basis for these discrepancies is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the biological mechanisms underlying discordant MRD and relapse status in AML.
• To explore the role of clonal ontogeny, including mutation dynamics and clonal architecture, in treatment response and resistance.
• To provide a framework for interpreting outlier MRD cases in AML.

Main Methods:

• Review of existing literature on clonal evolution in AML.
• Analysis of mutation patterns and clonal structures in patient cohorts.
• Application of Darwinian principles to model cancer progression and relapse dynamics.

Main Results:

• Identified distinct clonal evolutionary trajectories that explain MRD-leukemia discordance.
• Demonstrated how specific mutation profiles and clonal structures influence treatment sensitivity and resistance.
• Highlighted the dynamic nature of leukemia clones during and after therapy.

Conclusions:

• Clonal ontogeny provides a robust framework for understanding MRD prediction inaccuracies in AML.
• Interpreting MRD status requires consideration of the underlying leukemia clonal architecture and evolutionary potential.
• Further research into clonal dynamics can refine MRD assessment and guide personalized AML treatment strategies.